Aquestive Therapeutics (AQST) Fundamentals 2026 — Revenue Analysis | SniperIQ
Aquestive Therapeutics (AQST) is a US-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of
Aquestive Therapeutics (AQST) has a market capitalization of approximately
Aquestive Therapeutics runs a net profit margin of -137.1%, a gross margin of 63.5%, and an operating margin of -111.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Aquestive Therapeutics reported revenue of $45M for fiscal year 2025, with net income of -$84M and earnings per share (EPS) of -0.76. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Aquestive Therapeutics does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Aquestive Therapeutics carries a debt-to-equity ratio of -3.92x and a current ratio of 4.10x, with a market beta of 1.45. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Aquestive Therapeutics (AQST) the key facts are: market cap
Get Aquestive Therapeutics's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.